Chonnam Med J.
2000 Jun;36(2):179-185.
A Clinical Study for the Efficacy and Safety of Selegiline HCI(MAO-B(R)) in Parkinson's Disease
- Affiliations
-
- 1Department of Neurology, Chonnam National University Medical School, Kwangju, Korea.
- 2Department of Neurosurgery, Chonnam National University Medical School, Kwangju, Korea.
Abstract
- Selegiline HCl (MAO-B(R)) is a levorotatory acetylenic derivative of phenethylamine. The drug is an enzyme-activated irreversible inhibitor of monoamine oxidase (MAO), also known as mechanism-based, kcat, or "suicide" inhibitor. We carried out an open, non-comparative clinical study prospectively to investigate whether the disability of patients with Parkinson's disease could be improved during the first 3 months by Selegiline (MAO-B : 5-10 mg/day). Selegiline (MAO-B ) has been administered as monotherapy or combination with levodopa. A clinical trial was conducted over 3 months with 23 patients in our hospital. Sym- ptomatology was assessed on Unified Parkinson's Disease Rating Scale (UPDRS). Results obtained to data, indicate that UPDRS score was significantly improved at the end of 3 months. Adverse effects were rare and minor. Therefore, this study confirmed that Selegiline (MAO-B ) has proved itself to be a safe and effective monotherapy or adjuvant in long-term levodopa therapy of Parkinson's disease.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- MAO-inhibitors in Parkinson's Disease
- Platelet Monoamine Oxidase in Parkinson Patients:Effect of Deprenyl
- Monoamine Oxidase Inhibitors Attenuate Cytotoxicity of 1-Methyl-4-phenylpyridinium by Suppressing Mitochondrial Permeability Transition
- Xanthoangelol and 4-Hydroxyderricin Are the Major Active Principles of the Inhibitory Activities against Monoamine Oxidases on Angelica keiskei K
- MAO Inhibitors in Parkinson's Disease
